This month, we’re excited to feature UC-II®, a cutting-edge joint health ingredient revolutionising the way we think about collagen. Backed by science and driven by innovation, UC-II® offers powerful support for mobility and flexibility, making it a standout solution in the world of joint care. Additionally, we discuss future orders and an upcoming in-person event presenting the utility of Quatrefolic® Active Folate in skin health and beauty.
Ingredient Spotlight: UC-II®
By Dr Brad McEwen PhD, MHSc, MPH, BHSc
CMG Head of Products and Innovation
In recent weeks, UC-II® and CMG have gained media attention for their discussions surrounding the advantages of undenatured type II collagen (UC-II®) in promoting joint health. This interest has been fuelled by a growing body of research highlighting the potential benefits ofUC-II® in alleviating joint pain and improving mobility, particularly for individuals suffering from conditions such as osteoarthritis and rheumatoid arthritis. As a naturally occurring protein found in cartilage, UC-II® plays a crucial role in maintaining the structural integrity of joints. The unique properties of undenatured collagen allow it to interact with the immune system, potentially modulating inflammatory responses and promoting the body’s natural repair processes.
Chronic conditions are common and their incidence increases with age. In 2022, approximately 15.4 million individuals, representing 61% of the population across all age groups, were reported to be living with at least one of the identified long-term health issues. Specifically, it was estimated that 2.1 million males (16%) and 1.9million females (15%) were affected by back problems during the same year.
What is UC-II®
UC-II® supplies a unique patented form of collagen with undenatured type II collagen for joint health support. Unlike hydrolysed or denatured collagen, which is fragmented and broken down into peptides and amino acids during processing, UC-II® retains its native (undenatured) triple helix structure. The intact three-dimensional shape of undenatured type II collagen preserves the bioactive regions called epitopes. Once ingested, UC‑II® travels to the small intestine where it interacts with immune tissue in Peyer’s patches, a key site for inducing oral tolerance. Specialised dendritic (antigen-presenting) cells in Peyer’s patches process the UC‑II® epitopes and present them to naïve T helper (Th) cells. Upon encountering type II collagen, the induced regulatory T cells (T regs) release anti‑inflammatory cytokines, notably IL‑10 and transforming growth factor‑β (TGF‑β), which systemically downregulate inflammation. These cytokines play a vital role in downregulating systemic inflammation, thereby inhibiting the activation of autoreactive T helper and cytotoxic T cells that could potentially damage native type II collagen in joint cartilage.
Joint health is essential for maintaining an active lifestyle, and UC-II® offers a clinically backed solution in a convenient low dose of just 40 mg. This innovative ingredient has been shown to improve joint function, mobility, and flexibility, while increasing the range of motion in knee flexion and extension. Whether it’s standing upright, climbing stairs, bending, or squatting during physical activity,UC-II® helps reduce discomfort and supports smoother, more comfortable movement, making it a smart choice for anyone looking to stay active and pain-free.
UC-II® Improves Knee Joint Flexibility
A randomised, double-blind, placebo-controlled trial was carried out involving healthy individuals experiencing activity-related joint discomfort. The study included 96 participants aged between 20 and 55 years, who were divided into two groups: one receiving 40 mg of UC-II® and the other a placebo, over a duration of 24weeks. Results indicated a statistically significant improvement in knee flexion range of motion in the UC-II® group, with an increase of 3.23° compared to 0.21° in the placebo group (p = 0.025). Additionally, the UC-II® group demonstrated a significant enhancement in knee extension range of motion, with an increase of 2.21° over time (p = 0.0061), while the placebo group exhibited a non-significant increase of 1.27° (p > 0.05).
UC-II® Improves Knee Joint Extension
A randomised, double-blind, placebo-controlled study was conducted to evaluate the effects of UC-II® on knee function in healthy individuals without a history of arthritis who reported knee pain during intense physical activity. Participants received either 40 mg of UC-II® or a placebo daily for 120 days. Results indicated a statistically significant improvement in knee extension ability at day 120 for the UC-II® group compared to the placebo group (81.0 ± 1.3º vs 74.0 ± 2.2º,p = 0.011) and relative to baseline (81.0 ± 1.3º vs 73.2 ± 1.9º, p = 0.002).
UC-II® Reduces Knee Joint Discomfort and Improves Mobility
A randomised, parallel design and double-blind two-arm study was conducted of UC-II® vs Placebo for 24 weeks. The UC-II® group reported taking a higher number of daily steps at week 24 compared to the baseline value (+217 steps), whereas the placebo group reported a reduction in number of steps versus the baseline value (-530 steps). There were significant differences for knee pain (p=0.0482), knee twisting/pivoting (p=0.0346), walking while descending stairs (p=0.0215) and walking on a flat surface (p=0.0241) were observed after 24 weeks of UC-II® compared with placebo. The UC-II® group reported less pain after sporting activities.
Summary
In summary, UC-II® stands out as a low-dose (40 mg) joint health ingredient that delivers meaningful results. Backed by clinical research, it supports improved joint function, mobility, and flexibility, while significantly enhancing knee range of motion. Users have reported reduced pain during everyday movements such as standing, walking upstairs, bending, and squatting, especially during periods of increased physical activity. UC-II® offers a convenient and effective solution for those seeking lasting joint comfort and performance.